Cargando…
Features of Pharmacodynamics of the Anticoagulant Dabigatran in Secondary Thrombophilia
One of the crucial risk factors for development of severe postthrombotic disease (PTD) is the recurrence of deep vein thrombosis (DVT). New opportunities for pharmacological thromboprophylaxis of secondary thrombophilia were associated with the direct thrombin inhibitor—Dabigatran (Pradaxa; Boehring...
Autores principales: | Kairov, Gaisa T., Solovev, Maksim A., Kotlovskaya, Larisa Y., Udut, Vladimir V. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6714832/ https://www.ncbi.nlm.nih.gov/pubmed/30486664 http://dx.doi.org/10.1177/1076029618814344 |
Ejemplares similares
-
Dabigatran in the treatment and secondary prophylaxis of venous thromboembolism in children with thrombophilia
por: Brandão, Leonardo R., et al.
Publicado: (2022) -
Dabigatran in Cerebral Sinus Vein Thrombosis and Thrombophilia
por: Kellermair, Lukas, et al.
Publicado: (2022) -
Efficacy of Dabigatran in Pulmonary Embolism Due to Thrombophilia in Chronic Thromboembolic Pulmonary Hypertension
por: Muscoli, Saverio
Publicado: (2020) -
Promise and challenges of anticoagulation with dabigatran
por: Verma, Ashish, et al.
Publicado: (2012) -
Dabigatran Acylglucuronide, the Major Metabolite of Dabigatran, Shows a Weaker Anticoagulant Effect than Dabigatran
por: Kim, Jong-Min, et al.
Publicado: (2022)